Baseline risk characterization of early versus later adopters of long‐acting paliperidone palmitate formulations
Sign Up to like & getrecommendations! Published in 2022 at "Neuropsychopharmacology Reports"
DOI: 10.1002/npr2.12260
Abstract: Early Post‐Marketing Phase Vigilance (EPPV) is a unique system that encourages reporting of serious adverse reactions for medications newly introduced to Japan. When a once‐monthly paliperidone palmitate formulation (PP1M) was introduced in Japan in 2013,… read more here.
Keywords: baseline risk; paliperidone palmitate; mortality; risk ... See more keywords